Targeting ATR in Soft-tissue Sarcomas (TARSARC) is an ongoing Phase 2 randomised non-comparative trial of gemcitabine versus gemcitabine combined with the ATR inhibitor berzosertib in patients with advanced or metastatic leiomyosarcoma [93] (Table 1). Here, ATR is linked to soft tissue sarcoma.